Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil prices dip but hold near highest in a month on Middle East tensions
- Citi sees Google, Meta and Amazon capex spending at over $800 billion in 2027
- UnitedHealth shares surge on strong earnings beat and guidance
Canaccord Genuity Trims PT on Anacor Pharmaceuticals (ANAC), Keeps Buy
January 30, 2013 10:09 AM ESTCanaccord Genuity lowered its price target on Anacor Pharmaceuticals (NASDAQ: ANAC) from $9 to $5 but is keeping a Buy rating following phase 3 data on Tavaborole.
The firm comments, "Maintaining BUY but lowering target to $5 from $9 as tavaboroles potential in onychomycosis becomes... More
Anacor Pharma (ANAC) Reports Positive P-3 Data on Tavaborole for Onychomycosis
January 29, 2013 7:10 AM ESTAnacor Pharmaceuticals (NASDAQ: ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Tavaborole achieved a high... More
